Literature DB >> 21899971

Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis.

Yu-Yu Lu1, Jin-Hua Chen, Ji-An Liang, Hsin-Yi Wang, Cheng-Chieh Lin, Wan-Yu Lin, Chia-Hung Kao.   

Abstract

AIM: The purpose of the current study was to conduct a systemic review and meta-analysis of the published literature to evaluate the diagnostic accuracy of FDG PET or PET/CT in urinary bladder cancer.
MATERIALS AND METHODS: The authors conducted a systematic MEDLINE search of articles published between January 2000 and December 2010. Two reviewers independently assessed the methodological quality of each study. We conducted a meta-analysis of pooled sensitivity and specificity in detecting primary and metastatic lesions of bladder cancer.
RESULTS: Six studies met the inclusion criteria. The pooled sensitivity and specificity of PET/CT for primary lesion detection of bladder cancer were 0.90 (95% CI: 0.70-0.99) and 1.00 (95% CI: 0.74-1.00), respectively. The pooled sensitivity and specificity of FDG PET or PET/CT for staging or restaging (metastatic lesions) of bladder cancer were 0.82 (95% CI: 0.72-0.89) and 0.89 (95% CI: 0.81-0.95), respectively.
CONCLUSION: The diagnostic accuracy of FDG PET or PET/CT is good in metastatic lesions of urinary bladder cancer. Due to the small number of patients and limited number of studies analyzed, the diagnostic capability of FDG PET or PET/CT in detection of primary bladder wall lesions could not be assessed.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21899971     DOI: 10.1016/j.ejrad.2011.07.018

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  40 in total

Review 1.  Preoperative Imaging for Clinical Staging Prior to Radical Cystectomy.

Authors:  Cory M Hugen; Vinay Duddalwar; Siamak Daneshmand
Journal:  Curr Urol Rep       Date:  2016-09       Impact factor: 3.092

Review 2.  Preoperative imaging for staging bladder cancer.

Authors:  Maxim J McKibben; Michael E Woods
Journal:  Curr Urol Rep       Date:  2015-04       Impact factor: 3.092

Review 3.  Advances in Imaging in Prostate and Bladder Cancer.

Authors:  Abhishek Srivastava; Laura M Douglass; Victoria Chernyak; Kara L Watts
Journal:  Curr Urol Rep       Date:  2017-09       Impact factor: 3.092

4.  Comparing RECIST with EORTC criteria in metastatic bladder cancer.

Authors:  Hakan Öztürk
Journal:  J Cancer Res Clin Oncol       Date:  2015-07-25       Impact factor: 4.553

5.  Diagnostic value of [18F] FDG-PET and PET/CT in urinary bladder cancer: a meta-analysis.

Authors:  Huojun Zhang; Wei Xing; Qinqin Kang; Chao Chen; Linhui Wang; Jianping Lu
Journal:  Tumour Biol       Date:  2015-03-26

Review 6.  Advances in medical imaging for the diagnosis and management of common genitourinary cancers.

Authors:  Mohammad H Bagheri; Mark A Ahlman; Liza Lindenberg; Baris Turkbey; Jeffrey Lin; Ali Cahid Civelek; Ashkan A Malayeri; Piyush K Agarwal; Peter L Choyke; Les R Folio; Andrea B Apolo
Journal:  Urol Oncol       Date:  2017-05-12       Impact factor: 3.498

7.  Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET/CT.

Authors:  Pierpaolo Alongi; Federico Caobelli; Roberta Gentile; Alessandro Stefano; Giorgio Russo; Domenico Albano; Sergio Baldari; Maria Carla Gilardi; Massimo Midiri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-26       Impact factor: 9.236

8.  The influence of post-diuretic late phase imaging in visual and quantitative evaluation of urothelial tumors by F-18 fluorodeoxyglucose positron emission tomography/computed tomography.

Authors:  Zehra Pınar Koç; Pelin Özcan Kara; Emel Sezer; Kadir Eser
Journal:  Turk J Urol       Date:  2019-12-01

9.  [Functional imaging in bladder cancer].

Authors:  T Maurer; T Horn; A J Beer; M Eiber; J E Gschwend
Journal:  Urologe A       Date:  2013-04       Impact factor: 0.639

10.  PET/CT and MRI in Bladder Cancer.

Authors:  Kirsten Bouchelouche; Baris Turkbey; Peter L Choyke
Journal:  J Cancer Sci Ther       Date:  2012-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.